GlassScriptPhysician profile
Herbert Penix
NPI 1285137455
$3,238.56
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.67 · 2022: $654 · 2023: $1,427 · 2024: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $754.55 | 2022-2024 | |
| Novo Nordisk INC | $416.07 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $373.27 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $293.48 | 2022-2024 | |
| Lilly USA, LLC | $233.11 | 2022-2024 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $175.52 | 2024 | Voquezna |
| Pfizer INC. | $168.59 | 2023-2024 | |
| Exact Sciences Corporation | $163.17 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.50 | 2023-2024 | Trulance, Xifaxan |
| Abbott Laboratories | $77.73 | 2022-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $67.78 | 2022 | |
| Merck Sharp & Dohme LLC | $64.33 | 2023-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Dexcom, INC. | $61.01 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $54.19 | 2022-2024 | Veozah |
| Inspire Medical Systems, INC. | $43.19 | 2024 | Inspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.10 | 2023 | Trintellix |
| Lucid Diagnostics INC. | $35.76 | 2023 | |
| Axsome Therapeutics, INC. | $33.78 | 2023 | Auvelity |
| Glaxosmithkline, LLC. | $27.20 | 2022-2023 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $19.56 | 2022 | |
| Amgen INC. | $16.93 | 2023 | Repatha |
| Kowa Pharmaceuticals America, INC. | $14.98 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.76 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Penix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.